Objective: This study was conducted to determine the efficacy and safety of stent grafts in the treatment of thoracic aortic aneurysms and dissections. Method: Our health technology assessment method combined a critical review of the literature with experts' opinions. Several databases, useful Web sites, and the gray literature were searched from January 1995 to December 2004. Some manually retrieved major articles published in 2005 were also included. The draft report was submitted to and discussed by a working group of 12 members nominated by relevant medical societies. The amended report was submitted to a multidisciplinary group of 12 peer reviewers for comment. Results: Endovascular stent grafting (ESG) repair for lesions of the thoracic aorta, including aneurysms, dissections, and aortic isthmus ruptures, is probably beneficial in terms of operative mortality and severe morbidity, with an incidence of paraplegia of 2.1% (range 0%-7%) for ESG vs 5% (range, 3%-15%) for surgery, provided that there is a rigorous medium-term assessment and that anatomic factors are favorable. A proximal neck length of at least 2 cm is needed to insert the stent graft. Indications for ESG in thoracic aortic aneurysm and dissection are similar to those for surgery.
The two main degenerative diseases affecting the thoracic aorta (TA) are aneurysms (TAAs) and dissections (TADs). If left untreated, they may be life threatening. Treatment is medical or surgical, or both. The aim of medical treatment is to control blood pressure, but its efficacy is limited once symptoms have appeared (impending aneurysms, back pain, malperfusion syndrome) or when the degree of true lumen constriction exceeds two-thirds. At this stage of the disease, open surgery is the gold standard treatment; however, only patients with an acceptable surgical risk can benefit from open surgery because it may involve cardiopulmonary bypass. Endovascular stent grafting (ESG) might prove to be an acceptable alternative to open surgery.
One of the main activities of the Haute Autorité de Santé (HAS), or French National Authority for Health, is to assess drugs, medical devices, and procedures to encourage their proper use by professionals and to provide health authorities with the information they require to make decisions on reimbursement by National Health Insurance. The French Society of Vascular Surgery therefore asked HAS to assess the efficacy and safety of ESG in the treatment of TAAs and TADs. This article is based on a HAS report published in February 2006.
METHOD
The assessment report on ESG for TAAs and TADs was produced using an established method combining a critical appraisal of the literature and the opinion of a panel of experts recruited from several medical societies. We performed an electronic search of several bibliographic databases (MEDLINE, EMBASE, and PASCAL; articles in English or French) from January 1995 to December 2004 and consulted useful Web sites and the grey literature (eg, conference reports, fact sheets, patent applications, symposia, technical reports, etc). A manual search was used to retrieve major articles published in early 2005.
The following types of studies were included in our analysis:
1. comparative diagnostic and therapeutic studies on TA disease, regardless of sample size; 2. safety and efficacy studies on the treatment of atheromatous aneurysms, unruptured type B or traumatic dissections, intramural hematomas, and penetrating aortic ulcers (TA segments II and III), regardless of study design and evidence level;
3. studies on type B retrograde dissections of TA segment I (non-A, non-B TADs); and 4. recent good-quality reviews of TA surgery (including anesthesia), medical treatment of aneurysms and aortic dissections, TA imaging, and ESG.
We excluded studies on segment I TAAs, thoracoabdominal aneurysms, or patients presenting both thoracic and abdominal aneurysms because ESG may not be indicated in these cases. We also excluded cohort studies with Ͻ30 patients for combined TAA and TAD studies, Ͻ20 for TAA or TAD studies, Ͻ10 for traumatic aortic disease, intramural hematomas, or penetrating aortic ulcers. Finally, we excluded studies of homemade stent grafts because of device variability and absence of assessments during vigilance monitoring.
The results of the literature search and analysis are given in Table I . For each study, we determined internal validity (bias due to selection, nonblinding, and confounding variables) and external validity (population characteristics, follow-up, relevance of results). Validity was classified as "poor," "average" or "satisfactory." The HAS project manager produced a draft critical review of the literature that was submitted for discussion to a multidisciplinary working group of 15 members consisting of cardiologists, cardiac surgeons, vascular surgeons, vascular physicians, radiologists, engineers, anesthesiologists, and an account manager. Working group members were nominated by the relevant medical societies. An analysis of French ESG practice based on data from the Programme of Medicalization of Information Systems (PMSI) and from the Common Classification of Medical Procedures (CCAM), and on a description of care at Saint Joseph Hospital in Marseilles was included in the report. The amended report was then submitted to a multidisciplinary group of 12 peer reviewers for comment.
RESULTS

Study quality.
Seven nonrandomized, comparative studies (evidence level 2) were included in the 58 articles analyzed (Table II) . [1] [2] [3] [4] [5] [6] [7] Five of these studies compared surgical and endovascular treatments, one compared medical and endovascular treatments, and one concerned imaging techniques. Only the studies by Brandt et al 5 and Nienaber et al 2 compared ESG with conventional surgery in two groups of statistically comparable patients, either by identification of similar subpopulations or prospectively.
In the three other studies of ESG vs surgery, the demographic and clinical characteristics of the two groups of patients differed, with the ESG patients presenting a high comorbidity rate, such as high blood pressure, heart disease, or chronic pulmonary obstructive disease. 1, 3, 4 In the study by Ehrlich et al, 1 all the patients undergoing surgery could have been eligible for ESG; however, whereas all ESG patients had either coronary artery disease or a history of myocardial infarction, only 53% of the surgical patients did. In the study by Najibi et al, 3 the proportion of men and women was not the same in both groups. None of these three studies accounted for confounding factors. 1, 3, 4 The study by Bortone et al 6 compares ESG with medical treatment but makes no mention of a comparison between the groups under study.
Of the 58 studies analyzed, 34 (59%) were noncomparative cohort studies. The study of Ramaiah et al, 8 in which patients were split into two distinct series according to year of ESG treatment, was the only exception even if it was not a genuine comparative study. Whether the study was prospective or retrospective was specified in 22 of 34 (65%) studies (8 prospective, 14 retrospective), and the primary end point was clearly stated in 32 (94%). The number of patients to be included was rarely calculated: only three studies (9%) reported intention-to-treat results, and only nine (26.5%) performed an intention-to-treat analysis. Even if the methodologic quality of these cohort studies was rather poor, 31 (91%) reported results that directly concerned the primary end point. All of the studies addressed the clinical relevance of ESG and its use as a routine procedure. Patients formed representative samples of the populations usually treated for these diseases and not of the general population.
Efficacy of endovascular treatment of descending thoracic aorta disease regardless of cause. The technical success rate was mentioned in 31 studies and ranged from 77% to 100% according to study. The overall success rate was 94.6% (Table III) . [1] [2] [3] 7, Five studies defined technical success at the outset. [3] [4] [5] [6] [7] 28, 32 According to Czerny et al 12 and Taylor et al, 29 technical success is "perfect ESG deployment without primary leak." Leurs et al 20 completed this definition as follows: "successful ESG deployment in the absence of primary endoleak and intra-surgical complication." However, the latest definitions are given by Erbel et al, 23 "insertion and successful deployment of ESG without surgical conversion necessity nor per-surgical mortality, in the absence of type 1 or 3 endoleak, till the 24th post surgical hour," and by Najibi et al, 3 who reported the technical success rate at 30 days using the definition given by the Society of Vascular Surgery/International Society for Cardiovascular Surgery. The mean technical success rate in these five studies defining success rate was 88.8% (Table IV) .
Seven studies reported blood loss. Among them, 6 studies have quantified a total of 372 patients with a mean blood loss of 358.5 mL (range, 0-3000 mL). 3, 9, 17, 18, 21, 24 The mean surgical conversion rate, reported in 26 studies, was 1.4% (range, 0%-7.4%). Seven studies reported the ESG procedure lasted an average of 118 minutes (range, 37-580 minutes). The mean length of hospital stay in 17 of 19 studies documenting this variable was 6.6 days (range, 2.8-10 days) for a total of 542 patients. One study reported a mean length of stay of just 4 days. 9 In contrast, eight studies mentioned a mean length of stay in the intensive care unit of 2.9 days (range, 1.5-4.3 days) for a total of 384 interventions.
Death after endovascular treatment. The mean 30day mortality rate in 1756 patients from 31 studies was 6% (range, 0%-15%). Overall mortality, defined as deaths Յ30 days and during follow-up, was derived from 21 studies and was 0% to 28%. Of these 21 studies, 17 gave a mean follow-up that was used to calculate an overall mortality rate of 11.7% over an average of 18.4 months of follow-up. Seven studies provided actuarial survival rates, one of which reported a 2-year survival rate of Ͻ50%. 23 The survival rate in the other six studies was Ͼ80% at 2, 3, or 5 years 15, 20, 24, [26] [27] [28] and even reached 95% at 5 years (mean follow-up, 25 Ϯ 15 months) in the study by Fattori et al. 15 The 1-year survival rates were 80% and 90% in two studies 20, 25 and 47% and 84% in two others. 24, 26 Emergency patients were at much higher risk of death than those receiving elective treatment, whether in the case of ESG or open surgery. Of the 27 cohort studies that included surgical and endovascular repair, 11 distinguished death after elective and emergency surgery. Surgery was not reviewed in other articles. Emergency patients were a heterogeneous group, including traumatic ruptures with low mortality and TAA or TAD ruptures in patients with multiple comorbidities. A single study defined emergency treatment as treatment Յ48 hours of admission, symptomatic or fissured aneurysms, complicated Stanford type B aortic dissections, and traumatic aortic sections. 9 The mean 30day mortality rate in these 11 studies was 5.9% (range, 0%-16%) in electively treated patients and 16% (range, 2.5%-23%) in emergency cases. The overall mortality rate in seven studies was 13.3% (range, 4%-45%) in electively treated patients and 28.2% (range, 5%-38.5%) in emergency cases for a median follow-up of 20.5 months.
Endoleaks after endovascular treatment. Endoleaks are a specific complication of endovascular treatment. The HAS report used the endoleak classification given by White et al 33 for TAAs. Type I endoleaks are defined as an incomplete or ineffective seal at the proximal or distal end(s), or both, of the graft, and type II endoleaks as a retrograde blood flow from arterial branches. In TADs, the false lumen can also be perfused from distal re-entries and blood flow can circulate in a retrograde way; therefore, we prefer to use "false channel perfusion" instead of "endoleaks" in TADs.
The rate of early endoleaks was reported in 18 studies covering all types of TA disease. The mean rate was 10.5% (range, 0%-45%) for a total of 796 patients. No endoleaks were observed in three studies totalling 68 patients. The type of endoleak was specified in eight of 18 studies. 9, 15, 18, 23, [26] [27] [28] 31 In patients with an endoleak (13.4% of 371 patients), 76% of the endoleaks were type 1 leaks (remaining endoleaks at the end of the procedure), 20% were type 2, and 4% were type 3. No early type 4 endoleaks were observed.
Late endoleaks were reported in 18 further studies totalling 907 patients. The mean rate was 7.5% for a median follow-up of 17.9 months. Three studies totalling 93 patients reported a complete absence of endoleaks for a mean follow-up of at least 12 months. 2, 3, 10 Only six studies specified endoleak type: 61.8% were type 1 leaks, 23.5% were type 2 leaks, and 14.7% were type 3 leaks. No study mentioned a type 4 endoleak caused by porosity of the graft material.
Of the 21 selected studies specifying the disease being treated and distinguishing TAAs and TADs, nine reported an endoleak rate but without specifying the disease, three did not distinguish early and late endoleaks, 7, 24, 32 and only nine distinguished endoleaks in TAAs and circulating false lumens in TADs. The 814 procedures in these nine studies concerned 419 TAAs, 261 TADs, 87 aortic traumas (either TAA or TAD), and 47 procedures for other causes (Table  V) . 2, 6, 9, 14, 18, 20, 21, 29, 34 No endoleaks occurred in two studies of TAAs 6, 18 and two studies of TADs. 2, 31 The mean rate of endoleaks was highly similar for TAAs at 10.3% (range, 4%-30%) and TADs at 11.1% (range, 7%-47%). With a total of 32 procedures, the total rate of endoleaks for TAD was 6.25%.
Other complications after endovascular treatment. Technical, neurologic, and other complications are summarized in Table VI . Other types of complications were mentioned in 17 studies totalling 900 patients, the three main being renal insufficiency, respiratory complications, and scar complications.
DISCUSSION
Methodologic limitations.
Our assessment revealed the many methodologic limitations of studies on endovascular treatment of diseases of the TA. These limitations concerned:
• Study design. Most studies were cohort studies, including 27 retrospective (evidence level 5) and 11 prospective (level 3); six studies were reviews. Our assessment of clinical outcomes was based on 42 studies, most of which were cohort studies. Seven of these studies compared endovascular and conventional surgical treatment but nearly always in patient groups with dissimilar characteristics. The outcomes investigated were death at 30 days, paraplegia rate, operative time, intraoperative blood loss, and average length of stay in hospital.
Outcomes for endovascular treatment of dissections of the thoracic aorta. During the last 30 years, the prognosis of patients with aortic dissections has improved substantially. The European Echocardiographic Cooperative Study Group has reported 1-year post-ESG survival rates of 52%, 69%, and 70% and 2-year survival rates of 48%, 50%, and 60% for DeBakey types I, II (Stanford type A) and III (Stanford type B) dissections, respectively. 23 One-year survival rates of 34% and 85% for Stanford type A and B dissections, respectively, had been reported earlier. 35 Be- cause survival seems to depend on the degree of communication between the true and false lumen (ie, the pressure exercised over the wall within the false lumen), the prognosis of noncommunicating and retrograde Stanford type B dissections restricted to the descending aorta was better: the 2-year survival rates were 80% and 86%, respectively.
Endovascular treatment provides better outcomes than medical treatment. The International Registry of Acute Aortic Dissection (IRAD) study group reported mortality rates of 53% and 9% for Stanford types A and B (DeBakey I-III) dissections, respectively, after medical treatment compared with 27% and 29% after surgical treatment in a study of 464 patients. 36 The morbidity rates of endovascular treated TAAs and TADs were similar. Vascular access seemed to cause fewer complications because of flexible arteries, provided the stent graft was placed in the true lumen. Strokes after TADs were less frequent than after TAAs owing to the absence of atheromatous lesions of the aortic arch. However, supraaortic vessels could be the seat of dissection-induced malperfusion. The paraplegia rate was no higher for TADs than TAAs. Reports of aortic arch and ascending aorta retrograde dissection were rare. [37] [38] [39] Lethal mechanical complications have been reported, including rupture and fistulas between the aorta and esophagus or bronchus, related to the uncovered part of the stent graft. The use of this type of stent should be avoided.
Organization Patient selection depends on anatomic and clinical criteria to be discussed during multidisciplinary staff meetings in order to assess the benefit-risk ratios of the treatments offered.
Patients should be informed of the advantages and drawbacks of each procedure and of the conditions of long-term surveillance in order to be able to reflect on the options and make an informed choice. Provision of information to the patient will be put down in writing but does not imply that the patient has understood the information. The patient, or his or her family if appropriate, must give informed consent for the chosen treatment.
Postoperative surveillance will depend on the patient's clinical condition. On discharge from the hospital, the patient will be given a schedule of hospital visits and radiologic examinations, including computed tomography (CT) scanning or magnetic resonance imaging (MRI) plus thoracic radiograph. The French Agency for the Safety of Healthcare Products (AFSSAPS) has not yet issued guidelines for surveillance after endovascular treatment of TAAs and TADs. The recommended schedule for the abdominal aorta ESG should be applied in the meantime; that is, examinations on discharge from hospital or after 1 month, at 3 months if an early endoleak occurred, at 6, 12, 18, and 24 months, and yearly thereafter. Surveillance should be tailored to the patient and depends on endoleak occurrence, available equipment, and risks from radiation overexposure. The working group recommended that for reproducibility and reliability, radiologic examinations should be done whenever possible in the same center. Imaging reports should record the maximum aneurysm diameter, permeability, stent graft migration, periprosthetic leaks and, if appropriate, the perfusion of the false lumen at both thoracic and abdominal levels.
CONCLUSIONS
Endovascular treatment of thoracic aorta disease, including aneurysms, dissections, and traumatic disruption, is probably beneficial in terms of operative mortality and severe morbidity (incidence of paraplegia, 2.1% [range, 0%-7%] for ESG vs 5% [range, 3%-15%] for surgery), provided there is a rigorous medium-term assessment and provided that anatomic factors are favorable. In particular, a proximal neck length of at least 2 cm is needed to insert the stent graft. The indications for endovascular treatment are the same as those for open surgery. Endovascular stent grafting seems particularly appropriate in patients with multiple thoracic traumas in whom concomitant lesions are a contraindication to open surgery.
Treatment should be done in public or private centers with expertise in both endovascular and surgical procedures and with adequate technical facilities. Patients should be informed of the advantages and drawbacks of both methods. Endovascular stent graft treatment should be subject to prior multidisciplinary discussion, particularly with regard to risks of conversion and need for a cardiopulmonary bypass. Patients should be monitored annually by CT scan or MRI plus plain radiograph because long-term results are uncertain and include possible stent graft deterioration and onset of aortic disease. They should be told of the need for surveillance and possible further treatment.
Scientific evidence is currently of a low level. Randomized studies would be useful but are difficult to set up because patient numbers are small and catchment areas are very large. Data should be entered into a registry and be part of a medical device vigilance study within the establishment or be included prospectively in study currently comparing ESG with conventional surgery and medical treatment, or both, similar to the design of the Investigation of Stentgrafts in Aortic Dissection (INSTEAD) trial. A registry of all thoracic aorta interventions, including endovascular treatment, open surgery, thoracic ESG plus extra-anatomic bypass, and of follow-up data, accessible to all practitioners and device manufacturers, would have a number of advantages. It would (1) help identify the profiles of patients suitable for ESG treatment, (2) assess the practicability of a long-term randomized study comparing treatment modalities, (3) allow medium-term assessment of different devices, and (4) provide information for health economics studies. 
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